MORRISVILLE, N.C. — February 3, 2026 — Leads & Copy — Metabolon, Inc., a global leader in metabolomics solutions, has appointed Andrew (Drew) Messick as Chief Financial Officer.
Messick brings over 25 years of financial leadership experience to Metabolon. He has a track record of driving growth through financial and operational excellence in the life sciences sector, according to a news release. His expertise will be used as Metabolon scales and executes its strategic objectives.
Rohan Hastie, Ph.D., President and CEO of Metabolon, said Messick’s appointment strengthens Metabolon’s executive leadership team as the company expands its capabilities and market presence.
Messick has over a decade of experience leading finance and operations for privately held life sciences companies. Throughout his career, he has served as Chief Financial Officer for multiple organizations, building teams, optimizing processes, and navigating mergers and acquisitions.
Messick is a graduate of the University of North Carolina at Chapel Hill. He earned a Bachelor of Science in Business Administration and a Master of Accounting from UNC’s Kenan-Flagler Business School. He is a Chartered Financial Analyst (CFA) and a Certified Public Accountant (CPA). He resides in Cary, North Carolina, with his wife and three children.
Messick said Metabolon’s scientific leadership and multiomics capabilities position the company for long-term success. He is excited to join the team and support Metabolon’s continued growth through financial management and operational rigor.
Metabolon, Inc. delivers biochemical data and insights that expand the impact of life sciences research. The company has 25 years of experience, over 15,000 client projects, more than 4,000 scientific publication references, and ISO 9001:2015, CLIA, and CAP certifications. Metabolon’s Global Discovery Panel is powered by the world’s largest proprietary metabolomics reference library. The company offers multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management.
Metabolomics is the large-scale study of all small molecules in a biological system. It helps researchers see beyond genetic variation, capturing the combined impact of genetic and external factors on human health. By measuring chemical signals that form biological pathways, metabolomics can reveal biomarkers, enabling a better understanding of a drug’s mechanism of action, pharmacodynamics, and safety profile.
More information about Metabolon’s services can be found on their Global Discovery Panel: https://www.metabolon.com/resources/ebooks/global-panel/
Source: Metabolon, Inc.
